News | February 23, 2022
Biorchestra announces US$45 million series C fundraising
he financing was significantly oversubscribed with high demand from both existing and new investors.
he financing was significantly oversubscribed with high demand from both existing and new investors.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
Acute therapies continue to report strong growth compared to chronic ones.
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Subscribe To Our Newsletter & Stay Updated
